Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases (NELMAS)
An International Multicentre Randomized Unblinded Phase II Study Comparing Adjuvant Treatment With 177Lu-DOTATATE (Lutathera®) to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
Sponsor: Imperial College London
Terminated
The study has closed earlier than planned due to one of the funders decision to withdraw the financial support for the study.
A PHASE2 clinical study on Gastroenteropancreatic Neuroendocrine Neoplasm and Gastroenteropancreatic Neuroendocrine Tumor, this trial is terminated or withdrawn. The trial is conducted by Imperial College London and has accumulated 4 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Sep 2024 — Feb 2026 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Imperial College London
- Novartis/AAA
- The Taylor Family 2010 Charitable Trust
For direct contact, visit the study record on ClinicalTrials.gov .